Form 8-K - Current report:
SEC Accession No. 0001193125-21-325221
Filing Date
2021-11-10
Accepted
2021-11-10 06:56:06
Documents
14
Period of Report
2021-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d253452d8k.htm   iXBRL 8-K 24471
2 EX-99.1 d253452dex991.htm EX-99.1 65271
6 GRAPHIC g253452g1110013255943.jpg GRAPHIC 3026
  Complete submission text file 0001193125-21-325221.txt   229352

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA verv-20211110.xsd EX-101.SCH 2890
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE verv-20211110_lab.xml EX-101.LAB 18889
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE verv-20211110_pre.xml EX-101.PRE 11859
7 EXTRACTED XBRL INSTANCE DOCUMENT d253452d8k_htm.xml XML 3537
Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 211394325
SIC: 2834 Pharmaceutical Preparations